
Candel Therapeutics (CADL) Stock Forecast & Price Target
Candel Therapeutics (CADL) Analyst Ratings
Bulls say
Candel Therapeutics is viewed favorably because CAN-2409’s clinical profile remains compelling, with Phase 3 PrTK03 showing a 39% reduction in prostate cancer recurrence or prostate cancer-specific death versus placebo after a median 58 months of follow-up (n=745, HR 0.61, p=0.0031), plus supportive secondary and exploratory endpoint trends. That efficacy backdrop, combined with an intact Special Protocol Assessment and a BLA submission targeted for 4Q26, supports confidence in regulatory execution even as assay validation and CMC readiness create some timing and financing risk. Beyond prostate cancer, the first site activation for the global Phase 3 AURORA study in NSCLC and prior Phase 2a survival signals reinforce the case that its off-the-shelf viral immunotherapy platform could drive a multi-indication commercial opportunity.
Bears say
Candel Therapeutics is facing a meaningful setback because its expected CAN-2409 BLA submission slipped from 4Q26 to mid-2027 after the infectious-unit titer assay failed validation due to excessive variability, including between operators. Although process validation for drug substance and drug product has been executed and batches remain consistent, the filing still depends on resolving the assay, completing comparability and CMC work, and potentially other Tier 1 assay steps that are not yet fully finished. The delay pushes revenue and cash generation further out, while clinical, regulatory, commercial, competitive, and financing risks remain elevated, justifying the more cautious outlook.
This aggregate rating is based on analysts' research of Candel Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Candel Therapeutics (CADL) Analyst Forecast & Price Prediction
Start investing in Candel Therapeutics (CADL)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Candel Therapeutics (CADL) Forecast
Candel Therapeutics (CADL) Analyst Forecast & Price Prediction
Start investing in Candel Therapeutics (CADL)
Order type
Buy in
Order amount
Est. shares
0 shares